ID   M3K8_HUMAN              Reviewed;         467 AA.
AC   P41279; A8K2Q5; D3DRX1; Q14275; Q5T855; Q9HC81;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   15-MAR-2017, entry version 168.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 8;
DE            EC=2.7.11.25;
DE   AltName: Full=Cancer Osaka thyroid oncogene;
DE   AltName: Full=Proto-oncogene c-Cot;
DE   AltName: Full=Serine/threonine-protein kinase cot;
DE   AltName: Full=Tumor progression locus 2;
DE            Short=TPL-2;
GN   Name=MAP3K8; Synonyms=COT, ESTF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ONCOGENIC VARIANT.
RC   TISSUE=Hepatoma;
RX   PubMed=2072910; DOI=10.1128/MCB.11.8.4088;
RA   Miyoshi J., Higashi T., Mukai H., Ohuchi T., Kakunaga T.;
RT   "Structure and transforming potential of the human cot oncogene
RT   encoding a putative protein kinase.";
RL   Mol. Cell. Biol. 11:4088-4096(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=8226782;
RA   Aoki M., Sugimoto T., Sumida S., Hamada F., Akiyama T., Toyoshima K.;
RT   "The human cot proto-oncogene encodes two protein serine/threonine
RT   kinases with different transforming activities by alternative
RT   initiation of translation.";
RL   J. Biol. Chem. 268:22723-22732(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone;
RX   PubMed=8479752;
RA   Chan A.M., Chedid M., McGovern E.S., Popescu N.C., Miki T.,
RA   Aaronson S.A.;
RT   "Expression cDNA cloning of a serine kinase transforming gene.";
RL   Oncogene 8:1329-1333(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112.
RC   TISSUE=T-cell;
RX   PubMed=10896655; DOI=10.1074/jbc.M000382200;
RA   Sanchez-Gongora E., Lisbona C., de Gregorio R., Ballester A.,
RA   Calvo V., Perez-Jurado L., Alemany S.;
RT   "COT kinase proto-oncogene expression in T cells: implication of the
RT   JNK/SAPK signal transduction pathway in COT promoter activation.";
RL   J. Biol. Chem. 275:31379-31386(2000).
RN   [10]
RP   ALTERNATIVE INITIATION, FUNCTION, SUBCELLULAR LOCATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1833717;
RA   Aoki M., Akiyama T., Miyoshi J., Toyoshima K.;
RT   "Identification and characterization of protein products of the cot
RT   oncogene with serine kinase activity.";
RL   Oncogene 6:1515-1519(1991).
RN   [11]
RP   INTERACTION WITH NFKB1.
RX   PubMed=9950430; DOI=10.1038/16946;
RA   Belich M.P., Salmeron A., Johnston L.H., Ley S.C.;
RT   "TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory
RT   protein NF-kappaB1 p105.";
RL   Nature 397:363-368(1999).
RN   [12]
RP   FUNCTION.
RX   PubMed=11342626; DOI=10.4049/jimmunol.166.10.6084;
RA   Velasco-Sampayo A., Alemany S.;
RT   "p27kip protein levels and E2F activity are targets of Cot kinase
RT   during G1 phase progression in T cells.";
RL   J. Immunol. 166:6084-6090(2001).
RN   [13]
RP   INTERACTION WITH KSR2.
RX   PubMed=12975377; DOI=10.1074/jbc.M306002200;
RA   Channavajhala P.L., Wu L., Cuozzo J.W., Hall J.P., Liu W., Lin L.-L.,
RA   Zhang Y.;
RT   "Identification of a novel human kinase supporter of Ras (hKSR-2) that
RT   functions as a negative regulator of Cot (Tpl2) signaling.";
RL   J. Biol. Chem. 278:47089-47097(2003).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH NFKB1.
RX   PubMed=12667451; DOI=10.1016/S1097-2765(03)00070-4;
RA   Waterfield M.R., Zhang M., Norman L.P., Sun S.C.;
RT   "NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase
RT   signaling by governing the stability and function of the Tpl2
RT   kinase.";
RL   Mol. Cell 11:685-694(2003).
RN   [15]
RP   PHOSPHORYLATION AT THR-290, INTERACTION WITH KSR2, AND MUTAGENESIS OF
RP   THR-290.
RX   PubMed=15466476; DOI=10.1074/jbc.M403716200;
RA   Luciano B.S., Hsu S., Channavajhala P.L., Lin L.L., Cuozzo J.W.;
RT   "Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot
RT   is necessary but not sufficient for kinase activity.";
RL   J. Biol. Chem. 279:52117-52123(2004).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH NFKB1 AND TNIP2.
RX   PubMed=15169888; DOI=10.1128/MCB.24.12.5235-5248.2004;
RA   Lang V., Symons A., Watton S.J., Janzen J., Soneji Y., Beinke S.,
RA   Howell S., Ley S.C.;
RT   "ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is
RT   essential for TPL-2 protein stability.";
RL   Mol. Cell. Biol. 24:5235-5248(2004).
RN   [17]
RP   PHOSPHORYLATION AT THR-290.
RX   PubMed=15699325; DOI=10.1073/pnas.0409856102;
RA   Cho J., Tsichlis P.N.;
RT   "Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105
RT   and Tpl2 activation and degradation by lipopolysaccharide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:2350-2355(2005).
RN   [18]
RP   FUNCTION.
RX   PubMed=16371247; DOI=10.1016/j.cellsig.2005.10.016;
RA   Rodriguez C., Pozo M., Nieto E., Fernandez M., Alemany S.;
RT   "TRAF6 and Src kinase activity regulates Cot activation by IL-1.";
RL   Cell. Signal. 18:1376-1385(2006).
RN   [19]
RP   PHOSPHORYLATION AT THR-80; SER-400 AND SER-443.
RX   PubMed=17472361; DOI=10.1021/pr0700293;
RA   Black T.M., Andrews C.L., Kilili G., Ivan M., Tsichlis P.N.,
RA   Vouros P.;
RT   "Characterization of phosphorylation sites on Tpl2 using IMAC
RT   enrichment and a linear ion trap mass spectrometer.";
RL   J. Proteome Res. 6:2269-2276(2007).
RN   [20]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=19001140; DOI=10.1084/jem.20081461;
RA   Watford W.T., Hissong B.D., Durant L.R., Yamane H., Muul L.M.,
RA   Kanno Y., Tato C.M., Ramos H.L., Berger A.E., Mielke L., Pesu M.,
RA   Solomon B., Frucht D.M., Paul W.E., Sher A., Jankovic D.,
RA   Tsichlis P.N., O'Shea J.J.;
RT   "Tpl2 kinase regulates T cell interferon-gamma production and host
RT   resistance to Toxoplasma gondii.";
RL   J. Exp. Med. 205:2803-2812(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION AT SER-62; THR-290 AND SER-400, AND
RP   MUTAGENESIS OF SER-62; LYS-167; ASP-270; THR-290 AND SER-400.
RX   PubMed=19754427; DOI=10.1042/BJ20091271;
RA   Handoyo H., Stafford M.J., McManus E., Baltzis D., Peggie M.,
RA   Cohen P.;
RT   "IRAK1-independent pathways required for the interleukin-1-stimulated
RT   activation of the Tpl2 catalytic subunit and its dissociation from
RT   ABIN2.";
RL   Biochem. J. 424:109-118(2009).
RN   [23]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=19808894; DOI=10.2337/db09-0470;
RA   Jager J., Gremeaux T., Gonzalez T., Bonnafous S., Debard C.,
RA   Laville M., Vidal H., Tran A., Gual P., Le Marchand-Brustel Y.,
RA   Cormont M., Tanti J.F.;
RT   "Tpl2 kinase is upregulated in adipose tissue in obesity and may
RT   mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on
RT   extracellular signal-regulated kinase activation and lipolysis.";
RL   Diabetes 59:61-70(2010).
RN   [24]
RP   PHOSPHORYLATION AT SER-400.
RX   PubMed=22988300; DOI=10.1128/MCB.01065-12;
RA   Roget K., Ben-Addi A., Mambole-Dema A., Gantke T., Yang H.T.,
RA   Janzen J., Morrice N., Abbott D., Ley S.C.;
RT   "IkappaB kinase 2 regulates TPL-2 activation of extracellular signal-
RT   regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine
RT   400.";
RL   Mol. Cell. Biol. 32:4684-4690(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Required for lipopolysaccharide (LPS)-induced, TLR4-
CC       mediated activation of the MAPK/ERK pathway in macrophages, thus
CC       being critical for production of the proinflammatory cytokine TNF-
CC       alpha (TNF) during immune responses. Involved in the regulation of
CC       T-helper cell differentiation and IFNG expression in T-cells.
CC       Involved in mediating host resistance to bacterial infection
CC       through negative regulation of type I interferon (IFN) production.
CC       In vitro, activates MAPK/ERK pathway in response to IL1 in an
CC       IRAK1-independent manner, leading to up-regulation of IL8 and
CC       CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-
CC       cells and macrophages, and thus may play a role in the regulation
CC       of immunoglobulin production. May also play a role in the
CC       transduction of TNF signals that activate JNK and NF-kappa-B in
CC       some cell types. In adipocytes, activates MAPK/ERK pathway in an
CC       IKBKB-dependent manner in response to IL1B and TNF, but not
CC       insulin, leading to induction of lipolysis. Plays a role in the
CC       cell cycle. Isoform 1 shows some transforming activity, although
CC       it is much weaker than that of the activated oncogenic variant.
CC       {ECO:0000269|PubMed:11342626, ECO:0000269|PubMed:12667451,
CC       ECO:0000269|PubMed:15169888, ECO:0000269|PubMed:16371247,
CC       ECO:0000269|PubMed:1833717, ECO:0000269|PubMed:19001140,
CC       ECO:0000269|PubMed:19754427, ECO:0000269|PubMed:19808894}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Forms a ternary complex with NFKB1/p105 and TNIP2.
CC       Interacts with NFKB1; the interaction increases the stability of
CC       MAP3K8 but inhibits its MEK phosphorylation activity, whereas loss
CC       of interaction following LPS stimulation leads to its degradation.
CC       Interacts with CD40 and TRAF6; the interaction is required for ERK
CC       activation. Interacts with KSR2; the interaction inhibits ERK and
CC       NF-kappa-B activation. {ECO:0000269|PubMed:12667451,
CC       ECO:0000269|PubMed:12975377, ECO:0000269|PubMed:15169888,
CC       ECO:0000269|PubMed:15466476, ECO:0000269|PubMed:9950430}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-354900, EBI-352572;
CC       P19838:NFKB1; NbExp=13; IntAct=EBI-354900, EBI-300010;
CC       Q00653:NFKB2; NbExp=2; IntAct=EBI-354900, EBI-307326;
CC       Q13526:PIN1; NbExp=8; IntAct=EBI-354900, EBI-714158;
CC       Q8NFZ5:TNIP2; NbExp=10; IntAct=EBI-354900, EBI-359372;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:1833717,
CC       ECO:0000269|PubMed:8226782}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=58 kDa;
CC         IsoId=P41279-1; Sequence=Displayed;
CC       Name=2; Synonyms=52 kDa;
CC         IsoId=P41279-2; Sequence=VSP_018843;
CC   -!- TISSUE SPECIFICITY: Expressed in several normal tissues and human
CC       tumor-derived cell lines.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is activated specifically during
CC       the S and G2/M phases of the cell cycle.
CC   -!- INDUCTION: Up-regulated by IL12 in T-lymphocytes. Up-regulated in
CC       subcutaneous adipose tissue of obese individuals.
CC       {ECO:0000269|PubMed:19001140, ECO:0000269|PubMed:19808894}.
CC   -!- PTM: Autophosphorylated. Isoform 1 undergoes phosphorylation
CC       mainly on Ser residues, and isoform 2 on both Ser and Thr
CC       residues. Thr-290 is autophosphorylated (PubMed:19754427) and/or
CC       transphosphorylated (PubMed:15466476); the phosphorylation is
CC       necessary but not sufficient for full kinase activity in vitro and
CC       for the dissociation of isoform 1 from NFKB1, leading to its
CC       degradation. Ser-400 is autophosphorylated (PubMed:19754427)
CC       and/or transphosphorylated by IKBKB (PubMed:22988300); the
CC       phosphorylation is required for LPS-stimulated activation of the
CC       MAPK/ERK pathway in macrophages. {ECO:0000269|PubMed:15466476,
CC       ECO:0000269|PubMed:15699325, ECO:0000269|PubMed:17472361,
CC       ECO:0000269|PubMed:19754427, ECO:0000269|PubMed:22988300}.
CC   -!- MISCELLANEOUS: Can be converted to an oncogenic protein by
CC       proviral activation, leading to a C-terminally truncated protein
CC       with transforming activity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/map3k8/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D14497; BAA03387.1; -; mRNA.
DR   EMBL; Z14138; CAA78512.1; -; mRNA.
DR   EMBL; AK290320; BAF83009.1; -; mRNA.
DR   EMBL; AY309013; AAP45053.1; -; Genomic_DNA.
DR   EMBL; AL161651; CAI14227.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86004.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86005.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86006.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86007.1; -; Genomic_DNA.
DR   EMBL; BC104833; AAI04834.1; -; mRNA.
DR   EMBL; BC113566; AAI13567.1; -; mRNA.
DR   EMBL; AF133211; AAG13454.1; -; Genomic_DNA.
DR   CCDS; CCDS7166.1; -. [P41279-1]
DR   PIR; A48713; A48713.
DR   RefSeq; NP_001231063.1; NM_001244134.1. [P41279-1]
DR   RefSeq; NP_001307890.1; NM_001320961.1. [P41279-1]
DR   RefSeq; NP_005195.2; NM_005204.3. [P41279-1]
DR   RefSeq; XP_016871196.1; XM_017015707.1. [P41279-1]
DR   RefSeq; XP_016871197.1; XM_017015708.1. [P41279-1]
DR   RefSeq; XP_016871198.1; XM_017015709.1. [P41279-1]
DR   RefSeq; XP_016871199.1; XM_017015710.1. [P41279-1]
DR   UniGene; Hs.432453; -.
DR   UniGene; Hs.663033; -.
DR   UniGene; Hs.731448; -.
DR   PDB; 4Y83; X-ray; 2.89 A; A/B/C=66-395.
DR   PDB; 4Y85; X-ray; 2.33 A; A/B/C=66-395.
DR   PDB; 5IU2; X-ray; 2.70 A; A/B=66-395.
DR   PDBsum; 4Y83; -.
DR   PDBsum; 4Y85; -.
DR   PDBsum; 5IU2; -.
DR   ProteinModelPortal; P41279; -.
DR   SMR; P41279; -.
DR   BioGrid; 107719; 21.
DR   DIP; DIP-27534N; -.
DR   IntAct; P41279; 14.
DR   MINT; MINT-1140505; -.
DR   STRING; 9606.ENSP00000263056; -.
DR   BindingDB; P41279; -.
DR   ChEMBL; CHEMBL4899; -.
DR   GuidetoPHARMACOLOGY; 2083; -.
DR   iPTMnet; P41279; -.
DR   PhosphoSitePlus; P41279; -.
DR   BioMuta; MAP3K8; -.
DR   DMDM; 50403742; -.
DR   MaxQB; P41279; -.
DR   PaxDb; P41279; -.
DR   PeptideAtlas; P41279; -.
DR   PRIDE; P41279; -.
DR   DNASU; 1326; -.
DR   Ensembl; ENST00000263056; ENSP00000263056; ENSG00000107968. [P41279-1]
DR   Ensembl; ENST00000375321; ENSP00000364470; ENSG00000107968. [P41279-1]
DR   Ensembl; ENST00000542547; ENSP00000443610; ENSG00000107968. [P41279-1]
DR   GeneID; 1326; -.
DR   KEGG; hsa:1326; -.
DR   UCSC; uc001ivi.3; human. [P41279-1]
DR   CTD; 1326; -.
DR   DisGeNET; 1326; -.
DR   GeneCards; MAP3K8; -.
DR   HGNC; HGNC:6860; MAP3K8.
DR   HPA; CAB005120; -.
DR   HPA; HPA017962; -.
DR   MalaCards; MAP3K8; -.
DR   MIM; 191195; gene.
DR   neXtProt; NX_P41279; -.
DR   OpenTargets; ENSG00000107968; -.
DR   PharmGKB; PA30606; -.
DR   eggNOG; KOG0201; Eukaryota.
DR   eggNOG; ENOG410XP9G; LUCA.
DR   GeneTree; ENSGT00800000124036; -.
DR   HOGENOM; HOG000285978; -.
DR   HOVERGEN; HBG006306; -.
DR   InParanoid; P41279; -.
DR   KO; K04415; -.
DR   OMA; IHLFMEA; -.
DR   OrthoDB; EOG091G0682; -.
DR   PhylomeDB; P41279; -.
DR   TreeFam; TF105117; -.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SignaLink; P41279; -.
DR   SIGNOR; P41279; -.
DR   ChiTaRS; MAP3K8; human.
DR   GeneWiki; MAP3K8; -.
DR   GenomeRNAi; 1326; -.
DR   PRO; PR:P41279; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000107968; -.
DR   CleanEx; HS_MAP3K8; -.
DR   ExpressionAtlas; P41279; baseline and differential.
DR   Genevisible; P41279; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017424; MAPKKK8.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF038171; MAPKKK8; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; ATP-binding; Cell cycle;
KW   Complete proteome; Cytoplasm; Immunity; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    467       Mitogen-activated protein kinase kinase
FT                                kinase 8.
FT                                /FTId=PRO_0000024350.
FT   DOMAIN      138    388       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     144    152       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    253    253       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     167    167       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      62     62       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19754427}.
FT   MOD_RES      80     80       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17472361}.
FT   MOD_RES     141    141       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     290    290       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15466476,
FT                                ECO:0000269|PubMed:15699325,
FT                                ECO:0000269|PubMed:19754427}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000269|PubMed:17472361,
FT                                ECO:0000269|PubMed:19754427,
FT                                ECO:0000269|PubMed:22988300}.
FT   MOD_RES     443    443       Phosphoserine.
FT                                {ECO:0000269|PubMed:17472361}.
FT   VAR_SEQ       1     29       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8226782}.
FT                                /FTId=VSP_018843.
FT   VARIANT     214    214       S -> F (in dbSNP:rs3087944).
FT                                /FTId=VAR_051638.
FT   VARIANT     398    415       CQSLDSALLERKRLLSRK -> GHQVIHEGSSTNDPNNSC
FT                                (in oncogenic form).
FT                                /FTId=VAR_006198.
FT   VARIANT     416    467       Missing (in oncogenic form).
FT                                /FTId=VAR_006199.
FT   MUTAGEN      62     62       S->A: Decreased IL1-stimulated activity.
FT                                Loss of IL1-stimulated phosphorylation of
FT                                T-290 and MEK phosphorylation activity;
FT                                when associated with A-400.
FT                                {ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     167    167       K->R: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     270    270       D->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     290    290       T->A: Loss of MEK phosphorylation
FT                                activity and almost abolished
FT                                autophosphorylation activity. Loss of
FT                                IL1-stimulated MEK phosphorylation
FT                                activity but not of IL1-stimulated
FT                                autophosphorylation activity. No effect
FT                                on KSR2 binding.
FT                                {ECO:0000269|PubMed:15466476,
FT                                ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     290    290       T->D: Impaired MEK phosphorylation and
FT                                autophosphorylation activities. No effect
FT                                on KSR2 binding.
FT                                {ECO:0000269|PubMed:15466476,
FT                                ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     290    290       T->E: Loss of MEK phosphorylation
FT                                activity and almost abolished
FT                                autophosphorylation activity. No effect
FT                                on KSR2 binding.
FT                                {ECO:0000269|PubMed:15466476,
FT                                ECO:0000269|PubMed:19754427}.
FT   MUTAGEN     400    400       S->A: Slightly decreased IL1-stimulated
FT                                MEK phosphorylation activity. Loss of
FT                                IL1-stimulated phosphorylation of T-290
FT                                and MEK phosphorylation activity; when
FT                                associated with A-62.
FT                                {ECO:0000269|PubMed:19754427}.
FT   CONFLICT    399    399       Q -> T (in Ref. 1; BAA03387 and 2; no
FT                                nucleotide entry). {ECO:0000305}.
FT   STRAND       75     78       {ECO:0000244|PDB:4Y85}.
FT   HELIX        81     92       {ECO:0000244|PDB:4Y85}.
FT   STRAND      106    109       {ECO:0000244|PDB:4Y85}.
FT   STRAND      117    119       {ECO:0000244|PDB:4Y83}.
FT   TURN        124    126       {ECO:0000244|PDB:4Y85}.
FT   STRAND      127    130       {ECO:0000244|PDB:4Y85}.
FT   HELIX       135    137       {ECO:0000244|PDB:4Y83}.
FT   STRAND      138    145       {ECO:0000244|PDB:4Y83}.
FT   STRAND      148    157       {ECO:0000244|PDB:4Y85}.
FT   TURN        158    160       {ECO:0000244|PDB:4Y85}.
FT   STRAND      163    170       {ECO:0000244|PDB:4Y85}.
FT   HELIX       171    173       {ECO:0000244|PDB:4Y85}.
FT   HELIX       177    184       {ECO:0000244|PDB:4Y85}.
FT   STRAND      193    199       {ECO:0000244|PDB:4Y85}.
FT   STRAND      202    207       {ECO:0000244|PDB:4Y85}.
FT   HELIX       215    222       {ECO:0000244|PDB:4Y85}.
FT   HELIX       227    246       {ECO:0000244|PDB:4Y85}.
FT   HELIX       256    258       {ECO:0000244|PDB:4Y85}.
FT   STRAND      259    261       {ECO:0000244|PDB:4Y85}.
FT   STRAND      266    268       {ECO:0000244|PDB:4Y85}.
FT   STRAND      278    282       {ECO:0000244|PDB:4Y85}.
FT   HELIX       291    293       {ECO:0000244|PDB:4Y85}.
FT   HELIX       296    300       {ECO:0000244|PDB:4Y85}.
FT   HELIX       307    322       {ECO:0000244|PDB:4Y85}.
FT   TURN        326    330       {ECO:0000244|PDB:4Y85}.
FT   HELIX       340    346       {ECO:0000244|PDB:4Y85}.
FT   HELIX       350    352       {ECO:0000244|PDB:4Y85}.
FT   STRAND      355    357       {ECO:0000244|PDB:5IU2}.
FT   HELIX       359    368       {ECO:0000244|PDB:4Y85}.
FT   TURN        373    375       {ECO:0000244|PDB:4Y85}.
FT   HELIX       379    382       {ECO:0000244|PDB:4Y85}.
FT   HELIX       386    388       {ECO:0000244|PDB:4Y85}.
SQ   SEQUENCE   467 AA;  52925 MW;  7728969EA3E4E8EC CRC64;
     MEYMSTGSDN KEEIDLLIKH LNVSDVIDIM ENLYASEEPA VYEPSLMTMC QDSNQNDERS
     KSLLLSGQEV PWLSSVRYGT VEDLLAFANH ISNTAKHFYG QRPQESGILL NMVITPQNGR
     YQIDSDVLLI PWKLTYRNIG SDFIPRGAFG KVYLAQDIKT KKRMACKLIP VDQFKPSDVE
     IQACFRHENI AELYGAVLWG ETVHLFMEAG EGGSVLEKLE SCGPMREFEI IWVTKHVLKG
     LDFLHSKKVI HHDIKPSNIV FMSTKAVLVD FGLSVQMTED VYFPKDLRGT EIYMSPEVIL
     CRGHSTKADI YSLGATLIHM QTGTPPWVKR YPRSAYPSYL YIIHKQAPPL EDIADDCSPG
     MRELIEASLE RNPNHRPRAA DLLKHEALNP PREDQPRCQS LDSALLERKR LLSRKELELP
     ENIADSSCTG STEESEMLKR QRSLYIDLGA LAGYFNLVRG PPTLEYG
//
